Trone, Meuser Reintroduce the Bicameral, Bipartisan EFFECTIVE Act to Strengthen the FDA's Ability to Regulate Ineffective Opioids Entering the Drug Market
March 04, 2023
March 04, 2023
WASHINGTON, March 4 -- Rep. David Trone, D-Maryland, issued the following news release on March 3, 2023:
U.S. Congressmen David Trone (D-MD) and Dan Meuser (R-PA) reintroduced the Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement (EFFECTIVE) Act to allow the FDA to deny a new drug application for an opioid if it is not clinically superior to other commercially available drugs.
In February 2023, the Food and Drug Administration (FDA) . . .
U.S. Congressmen David Trone (D-MD) and Dan Meuser (R-PA) reintroduced the Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement (EFFECTIVE) Act to allow the FDA to deny a new drug application for an opioid if it is not clinically superior to other commercially available drugs.
In February 2023, the Food and Drug Administration (FDA) . . .